RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN417.09m
- PLN434.44m
- PLN62.25m
Brief: Ryvu Therapeutics Achieves First Milestone Under Agreement With Exelixis
Brief: BioNTech Holds 8.29% Stake In Ryvu Therapeutics
Brief: Ryvu Therapeutics Allots 4.8 Mln J Series Shares
Brief: Ryvu Therapeutics Sets J Series Share Price For BioNTech At 48.86 Zlotys/SHR
Polish biotech firm Ryvu Therapeutics aims to raise 272 million zlotys in public offering
Brief: Ryvu Therapeutics To Issue Up To 4.8 Million J Series Shares In December
Brief: Ryvu Therapeutics Signs Cooperation, Licence And Investment Deal With BioNTech
Brief: Biontech And Ryvu Therapeutics To Develop And Commercialize Immuno-Modulatory Small Molecule Candidates
Brief: Ryvu Therapeutics Q3 Net Loss Narrows To 11.8 Mln Zlotys
Brief: Ryvu Therapeutics SA Says RVU120 Was Well Tolerated Across All Doses Evaluated
Brief: Ryvu Therapeutics To Issue Up To 4.8 Mln J Series Shares
Brief: Ryvu Therapeutics Q2 Net Loss Widens To 36.9 Mln Zlotys
Brief: Ryvu Therapeutics Presents Development Plans For 2022-2024
Brief: Ryvu Therapeutics Signs Financing Deal For Up To EUR 22 Mln With EIB
Brief: Ryvu Therapeutics Says Established Exclusive License Agreement With Exelixis To Develop Novel Sting Agonist-Based Targeted Cancer Therapies
Brief: Ryvu Therapeutics Presents Updated Data On RVU120 At 2022 EHA Congress
Brief: Ryvu Therapeutics Q1 Net Loss Widens To 26.5 Mln Zlotys
Brief: Ryvu Therapeutics FY Net Loss Widens To 77.5 Mln Zlotys
Brief: Selvita Unit Gets $4.7 Mln Order From US-Based Client